Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL10379555 | 0.91 | CETP (0.56) | CETPTSHRFUCA1DNM1 | |
| SCHEMBL11372702 | 0.87 | CETP (0.56) | CETPLMNAESR1ADORA3CDC25A | |
| Tetramethylammonium Ion SCHEMBL9937868 | 0.82 | TSHR (0.55) | CETPTSHRFUCA1 | |
| SCHEMBL7861818 | 0.80 | TSHR (0.61) | CETPTSHRFUCA1LMNA | |
| SCHEMBL5437520 | 0.80 | TSHR (0.61) | CETPTSHRFUCA1LMNA | |
| SCHEMBL28669438 | 0.80 | TSHR (0.61) | CETPTSHRFUCA1LMNA | |
| Potassium Ion SCHEMBL4956047 | 0.80 | TSHR (0.61) | CETPTSHRFUCA1LMNA | |
| SCHEMBL10689581 | 0.80 | TSHR (0.61) | CETPTSHRFUCA1 | |
| SCHEMBL11756561 | 0.80 | TSHR (0.61) | CETPTSHRFUCA1LMNA | |
| Lithium Ion SCHEMBL9446519 | 0.80 | TSHR (0.61) | CETPTSHRFUCA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277190-A1 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR | ABBVIE INC. | 2012-11-01 | — | — | US | disclosed |
| US-8232309-B2 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| EP-1957464-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR | Abbott Laboratories (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7335500-B2 | Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-02-26 | — | — | US | disclosed |
| WO-2007050732-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR | ABBOTT LABORATORIES (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| CN-1124846-C | N, N' -bis (sulfonyl) hydrazines as antitumor agents | UNIV YALE (US) | 2003-10-22 | — | — | CN | disclosed |
| EP-1028721-B1 | N,N'-BIS(SULFONYL)HYDRAZINES USEFUL AS ANTINEOPLASTIC AGENTS | UNIV YALE (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-0747385-B1 | Prodrugs of paclitaxel derivatives | BRISTOL MYERS SQUIBB CO (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020068331-A1 | Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose | WONG CHI-HUEY (US) | 2002-06-06 | — | — | US | disclosed |
| CN-1066151-C | Prodrugs of paclitaxel derivatives | BRISTOL MYERS SQUIBB CO (US) | 2001-05-23 | — | — | CN | disclosed |
| CN-1278169-A | N, N' -bis (sulfonyl) hydrazines as antitumor agents | UNIV YALE (US) | 2000-12-27 | — | — | CN | disclosed |
| US-6040338-A | N,n-bis(sulfonyl)hydrazines useful as antineoplastic agents | YALE UNIVERSITY (US) | 2000-03-21 | — | — | US | disclosed |
| CN-1237580-A | Phosphononooxymethyl ethers of taxame derivatives | BRISTOL MYERS SQUIBB CO (US) | 1999-12-08 | — | — | CN | disclosed |
| EP-0642526-B1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | SCRIPPS RESEARCH INST (US) | 1998-12-23 | — | — | EP | disclosed |
| CN-1144805-A | Prodrugs of paclitaxel derivatives | BRISTOL MYERS SQUIBB CO (US) | 1997-03-12 | — | — | CN | disclosed |
| EP-0747385-A1 | Prodrugs of paclitaxel derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0642526-A4 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE. | SCRIPPS RESEARCH INST (US) | 1996-04-10 | — | — | EP | disclosed |
| EP-0642526-A1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993008205-A1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277190-A1 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR | TRPV1, TRPV3, TRPA1 | CETP 4409/4885TSHR 2169/4885FUCA1 2731/4885 |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | TRPV1, TRPV3, TRPA1 | CETP 4409/4885TSHR 2169/4885FUCA1 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.